Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316164 | 0.89 | TDP1 (0.36) | TDP1 | |
| SCHEMBL20397455 | 0.85 | — | — | |
| SCHEMBL21897421 | 0.83 | TDP1 (0.36) | TDP1 | |
| SCHEMBL24393502 | 0.81 | ESR1 (0.33) | TDP1 | |
| SCHEMBL21413416 | 0.75 | TDP1 (0.40) | TDP1 | |
| SCHEMBL93815 | 0.73 | MEN1 (0.50) | TDP1MEN1KMT2A | |
| SCHEMBL10289401 | 0.73 | CA12 (0.44) | TDP1MEN1KMT2A | |
| SCHEMBL24393622 | 0.73 | HDAC6 (0.38) | — | |
| SCHEMBL6655680 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL896953 | 0.71 | MEN1 (0.48) | TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11351222-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220160819-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20190282654-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2019-09-19 | — | — | US | disclosed |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282654-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | IKBKE, IKBKB, SHARPIN | TDP1 3576/4885MEN1 3369/4885KMT2A 4308/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | TDP1 3147/4885MEN1 3890/4885KMT2A 1891/4885 |
| US-20220160819-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | IKBKE, IKBKB, SHARPIN | TDP1 3576/4885MEN1 3369/4885KMT2A 4308/4885 |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | TDP1 2978/4885MEN1 2662/4885KMT2A 117/4885 |
| US-11351222-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | IKBKE, IKBKB, SHARPIN | TDP1 3576/4885MEN1 3369/4885KMT2A 4308/4885 |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SSB, UACA, CDA | TDP1 1488/4885MEN1 515/4885KMT2A 199/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | TDP1 3153/4885MEN1 4233/4885KMT2A 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.